BLACKROCK HLTH SCI TRM TR II (BMEZ) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:BMEZ - US09260E1055
BMEZ Key Statistics, Chart & Performance
The current stock price of BMEZ is 15.59 USD. In the past month the price increased by 3.66%. In the past year, price decreased by -0.45%.
BMEZ Latest News, Press Relases and Analysis
BLACKROCK HLTH SCI TRM TR II / BMEZ FAQ
What does BLACKROCK HLTH SCI TRM TR II do?
BlackRock Health Sciences Term Trust is a US-based company operating in industry. The company is headquartered in Wilmington, Delaware. The company went IPO on 2020-01-29. BlackRock Health Sciences Term Trust (the Trust) is a closed-end management investment trust. The Trust’s investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation. The Trust invests at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries. Trust may also invest in companies of any market capitalization located anywhere in the world, including companies located in emerging markets. The Trust focuses on small and mid-sized healthcare companies. The Trust invests in industries, such as biotechnology, life sciences tools and services, pharmaceuticals, financial services, health care technology, hotels, restaurants and leisure, and others. The Trust’s investment adviser is BlackRock Advisors, LLC.
Can you provide the latest stock price for BLACKROCK HLTH SCI TRM TR II?
The current stock price of BMEZ is 15.59 USD. The price decreased by -0.38% in the last trading session.
What is the ChartMill technical and fundamental rating of BMEZ stock?
BMEZ has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
BMEZ Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to BMEZ. When comparing the yearly performance of all stocks, BMEZ turns out to be only a medium performer in the overall market: it outperformed 60.58% of all stocks.